Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Acceleron Pharma Inc | NASDAQ:XLRN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 178.75 | 179.92 | 179.91 | 0 | 00:00:00 |
From Nov 2019 to Nov 2024
By Dave Sebastian
Merck & Co. has agreed to buy Acceleron Pharma Inc. for $11.5 billion, bolstering the pharmaceutical giant's rare-disease business.
The deal values Acceleron at $180 a share in cash, the companies said Thursday. The Wall Street Journal on Monday reported that the companies were nearing a deal.
The deal is one of Merck's biggest and represents a bet on treatments for respiratory and blood diseases that Acceleron specializes in. Acceleron's crown jewel is an experimental drug for pulmonary arterial hypertension, a disease caused by high pressure in the blood vessels leading from the heart to the lungs.
The companies expect the deal to close in the fourth quarter.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
September 30, 2021 07:19 ET (11:19 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Acceleron Pharma Chart |
1 Month Acceleron Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
